Showing results (21-30 of 1,472) with videos related to

Sort By:
Pageof 148
The Journal of Allergy and Clinical Immunology|July 29, 1998
A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study GroupL C Altman, Z Munk, J Seltzer, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|December 1, 1989
Effect of exercise, hyperpnea, and bronchoconstriction on plasma atrial natriuretic peptideI Rubinstein, T F Reiss, D G Gardner, et al.
Thorax|January 1, 1997
Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsT F Reiss, C A Sorkness, W Stricker, et al.
The European Respiratory Journal|March 1, 1997
Measurement characteristics of two asthma symptom diary scales for use in clinical trialsN C Santanello, B L Barber, T F Reiss, et al.
JAMA|April 29, 1998
Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study GroupB Knorr, J Matz, J A Bernstein, et al.
The Journal of Infection|December 3, 2005
Corynebacterium minutissimum pyelonephritis with associated bacteraemia: a case report and review of literatureNasir M Ahmad, Khalid M Ahmad
Respiratory Medicine|June 8, 2001
Analysis of montelukast in mild persistent asthmatic patients with near-normal lung functionN Barnes, L X Wei, T F Reiss, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 1999
Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity GroupM Laviolette, K Malmstrom, S Lu, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 13, 2001
Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 yearsW Storms, T M Michele, B Knorr, et al.
Thorax|March 28, 1998
Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonistT F Reiss, J B Hill, E Harman, et al.
Pageof 148